A Phase 3 Randomized Double-blind Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II IIIA IIIB (N2) Non-small Cell Lung Cancer

Brief description of study

This clinical study will evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II to IIIB (N2) NSCLC.


Clinical Study Identifier: s23-01240
ClinicalTrials.gov Identifier: NCT06077760
Principal Investigator: Vamsidhar Velcheti.
Other Investigators: Joshua K Sabari, Samantha VanMaanen, Elka R Travis, Jessica Wang, Elaine Shum, Salman Rafi Punekar, Sally Lau, Danny Perlaza, Marissa Rybstein, David Mendoza, Natalia Cherkassky, James Newman, Jeffrey G Schneider, Melissa L Martinez, Kirby Rodriguez.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.